Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut
Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.
Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody
Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.
LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?
LEO Pharma has won China approval for Enstilar in plaque psoriasis. Read what it means for competition, access, and dermatology growth.
Can Takeda’s zasocitinib change the plaque psoriasis treatment ladder after Phase 3 wins?
Takeda’s zasocitinib posted strong Phase 3 psoriasis data. Read what it changes for TYK2 competition, regulation, and oral treatment strategy.
Takeda’s zasocitinib hits key Phase 3 psoriasis goals, challenging oral and biologic rivals
Takeda Pharmaceutical Company Limited has reported positive topline results from two pivotal Phase 3 studies of its investigational drug zasocitinib (TAK-279), a once-daily oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The trials met all primary and secondary endpoints, with more than 50 percent of participants achieving near-complete skin clearance (PASI […]